The antiviral drug ensitrelvir, which shortens sensory problems, is one of the few COVID-19 drugs available to people not at high risk of grave illness.
The antiviral drug ensitrelvir, which shortens sensory problems, is one of the few COVID-19 drugs available to people not at high risk of grave illness.
From the article:
Unless I’m misreading this, they saw some notable reduction in symptoms at 1 week, but the benefit had faded away by the time they hit three weeks. This seems to imply that the drug doesn’t provide any reduction in long-term loss of smell (or at least, such a benefit was not shown in this particular trial).
Yeah, that’s how I’m reading it as well